Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE led to higher adverse effects: 1. Sedation compared with RISPERIDONE; GRADE not reported.
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with RISPERIDONE (moderate certainty).
1 finding from 1 review
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Subjective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology (PANSS) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Objective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology ‐ various scales · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Death by end of trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in death Reported by trial author compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate showed no clear difference in relapse: recurrence of psychotic symptoms Reported by trial authors… compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review